Corvus Pharmaceuticals (FRA:C17) Short Interest


FRA:C17 Corvus Pharmaceuticals Inc FRA:C17
32 GF Score
Price €11.07
! 1 Warning Sign
View Full Analysis

What is Corvus Pharmaceuticals Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:C17 vs JBIO, ABSI, SVRA: Short Interest Comparison

For the Biotechnology subindustry, Corvus Pharmaceuticals's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Corvus Pharmaceuticals Short Interest vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corvus Pharmaceuticals's Short Interest distribution charts can be found below:

* The bar in red indicates where Corvus Pharmaceuticals's Short Interest falls into.


FRA:C17
32GF Score
Corvus Pharmaceuticals Inc FRA:C17
Short Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Corvus Pharmaceuticals Business Description

Other Exchanges CRVS:USAC17:Germany
Address 901 Gateway Boulevard, Third Floor, South San Francisco, CA, USA, 94080
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
32GF Score

Get the complete analysis for FRA:C17

Short Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€11.07
Price